BOSS Trial
The aim of the study is to see whether regular endoscopic surveillance is better than endoscopy at need for detecting early signs of oesophageal cancer in patients diagnosed with Barrett’s oesophagus.
On this page
About BOSS
This trial is funded by the National Institute of Health Research through the NIHR Health Technology Assessment Programme and run by the Research & Development team based at Gloucestershire Hospitals NHS Foundation Trust. 3,400 patients (1,700 in each group) have been recruited to the trial over a 3-year period with follow up continuing for 10 years.
The aim of the study is to see whether regular endoscopic surveillance is better than endoscopy at need for detecting early signs of oesophageal cancer in patients diagnosed with Barrett’s oesophagus.
The study patients have been randomised to receive a standard upper gastrointestinal endoscopy with biopsy every two years for ten years or endoscopy at need. Those patients randomised to endoscopy at need are free to request an endoscopy at any time if they have concerns (this also applies to those allocated to the two-yearly endoscopy arm).
Recruitment and follow-up for the BOSS trial is now complete and plans for the analysis and report writing are currently in progress.
Newsletters
Meet the Team
- Professor Hugh Barr, Chief Investigator, 0300 422 6679
- Mr Oliver Old, Joint Chief Investigator, 0300 422 6226
- Catherine Kendall, Trial Manager, 0300 422 5470
- Clive Stokes, Trial Coordinator, 0300 422 5477
- Allison Bates, Trial Administrator, 0300 422 5484
- Angela Moulsdale, Data Officer, 0300 422 5482
Contact
BOSS Trial Team
Chestnut House
Gloucestershire Royal Hospital
Great Western Road
Gloucester
GL1 3NN
ghn-tr.BOSS@nhs.net